Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Eyegate Pharmaceuticals Inc. EYEGV

Healthcare Biotechnology

Recent & Breaking News (GREY:EYEGV)

Eyegate Pharmaceuticals to Present at the Noble Financial Capital Markets' 12th Annual Investor Conference

GlobeNewswire January 14, 2016

EyeGate Reports Third Quarter 2015 Financial Results and Provides Business Update

GlobeNewswire November 12, 2015

EyeGate Announces Interim Data From Phase 1b / 2a Clinical Trial of Iontophoretic EGP-437 Ophthalmic Solution in Macular Edema Patients

GlobeNewswire November 5, 2015

EyeGate Pharma Receives USPTO Notice of Allowance for Next Generation of Proprietary Iontophoretic Delivery System

GlobeNewswire October 15, 2015

Eyegate Pharmaceuticals to Present at the 17th Rodman and Renshaw 2015 Annual Global Investment Conference

GlobeNewswire September 1, 2015

Eyegate Pharmaceuticals Announces Closing of Public Offering of Common Stock and Warrants

GlobeNewswire August 5, 2015

EyeGate Pharmaceuticals Announces Pricing of $10,000,000 Public Offering of Common Stock and Warrants

GlobeNewswire July 30, 2015

EyeGate Pharma Receives USPTO Notice of Allowance for Proprietary Dexamethasone Phosphate Formulation

GlobeNewswire July 24, 2015

EyeGate Pharma Receives USPTO Notice of Allowance for Proprietary Dexamethasone Phosphate Formulation

GlobeNewswire July 24, 2015

EyeGate Pharma Treats First Patient in Phase 1b / 2a Trial of EGP-437 in Macular Edema

GlobeNewswire July 14, 2015

EyeGate Signs Licensing Agreement with Valeant Pharmaceuticals for EGP-437 Combination Product in Uveitis

GlobeNewswire July 10, 2015

EyeGate Pharma Receives Positive Guidance From FDA on NDA Filing Requirements of EGP-437 for the Treatment of Anterior Uveitis

GlobeNewswire May 4, 2015

EyeGate Pharmaceuticals Reports Full Year 2014 Financial Results

GlobeNewswire March 31, 2015

Eyegate Pharmaceuticals Names Michael B. Raizman, MD, Consulting Chief Medical Officer

GlobeNewswire March 2, 2015

Eyegate Pharmaceuticals, Inc. Announces Closing of Initial Public Offering of Approximately $4,100,000 of Common Stock

GlobeNewswire February 19, 2015

Eyegate Pharmaceuticals, Inc. Prices $4,100,000 Initial Public Offering

GlobeNewswire February 12, 2015